Zynex (NASDAQ:ZYXI) Price Target Cut to $8.00 by Analysts at HC Wainwright

Zynex (NASDAQ:ZYXI - Get Free Report) had its price target lowered by investment analysts at HC Wainwright from $15.00 to $8.00 in a research note issued on Wednesday,Benzinga reports. The brokerage presently has a "buy" rating on the stock. HC Wainwright's price target indicates a potential upside of 246.32% from the company's previous close. HC Wainwright also issued estimates for Zynex's Q2 2025 earnings at ($0.20) EPS, Q3 2025 earnings at ($0.20) EPS, Q4 2025 earnings at ($0.19) EPS, FY2025 earnings at ($0.92) EPS, Q1 2026 earnings at ($0.18) EPS, Q2 2026 earnings at ($0.14) EPS, Q3 2026 earnings at ($0.12) EPS, Q4 2026 earnings at ($0.12) EPS and FY2026 earnings at ($0.56) EPS.

A number of other equities research analysts have also weighed in on ZYXI. Royal Bank of Canada reaffirmed a "sector perform" rating on shares of Zynex in a research note on Tuesday, April 15th. LADENBURG THALM/SH SH lowered Zynex from a "buy" rating to a "neutral" rating in a research report on Wednesday, March 12th.

Zynex Trading Up 14.9 %

ZYXI traded up $0.30 during trading on Wednesday, hitting $2.31. 334,065 shares of the stock traded hands, compared to its average volume of 157,801. The firm has a market capitalization of $69.82 million, a P/E ratio of 15.40 and a beta of 1.09. Zynex has a 12-month low of $1.66 and a 12-month high of $11.81. The company has a debt-to-equity ratio of 1.66, a current ratio of 3.94 and a quick ratio of 3.15. The firm has a 50-day moving average of $3.35 and a 200 day moving average of $6.47.

Zynex (NASDAQ:ZYXI - Get Free Report) last posted its earnings results on Monday, April 28th. The company reported ($0.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.09). The business had revenue of $26.58 million during the quarter, compared to the consensus estimate of $30.83 million. Zynex had a return on equity of 13.05% and a net margin of 2.49%. Equities research analysts anticipate that Zynex will post 0.2 EPS for the current year.

Insiders Place Their Bets

In other Zynex news, CFO Daniel J. Moorhead sold 10,000 shares of the stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $7.15, for a total transaction of $71,500.00. Following the sale, the chief financial officer now directly owns 10,050 shares in the company, valued at approximately $71,857.50. This trade represents a 49.88 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 49.28% of the company's stock.

Hedge Funds Weigh In On Zynex

Hedge funds have recently bought and sold shares of the business. Investment Partners Asset Management Inc. raised its holdings in shares of Zynex by 10.4% during the fourth quarter. Investment Partners Asset Management Inc. now owns 12,942 shares of the company's stock valued at $104,000 after purchasing an additional 1,220 shares during the last quarter. JPMorgan Chase & Co. raised its stake in Zynex by 3.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 40,985 shares of the company's stock valued at $334,000 after buying an additional 1,318 shares during the last quarter. Bank of America Corp DE lifted its holdings in shares of Zynex by 6.2% during the 4th quarter. Bank of America Corp DE now owns 24,114 shares of the company's stock valued at $193,000 after buying an additional 1,407 shares during the period. American Century Companies Inc. boosted its stake in shares of Zynex by 4.4% in the 4th quarter. American Century Companies Inc. now owns 35,696 shares of the company's stock worth $286,000 after buying an additional 1,516 shares during the last quarter. Finally, Connors Investor Services Inc. grew its holdings in shares of Zynex by 5.7% in the fourth quarter. Connors Investor Services Inc. now owns 29,858 shares of the company's stock worth $239,000 after acquiring an additional 1,608 shares during the period. Hedge funds and other institutional investors own 29.68% of the company's stock.

Zynex Company Profile

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.